TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06991114: AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Dis

Sponsor: Artiva Biotherapeutics, Inc. · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 90 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,656,500

Rescue Site Savings

+$1,759,500

Unlock Full NCT06991114 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06991114 Rescue Dossier →